Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch-related responses in mice with chronic atopy-like dermatitis

Experimental Dermatology

Volumn 23, Issue 5, 2014, Pages 359-361

  Andoh, Tsugunobu ^a   Yoshida, Tetsuro ^a   Kuraishi, Yasushi ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Atopic dermatitis; CAMP; Itch; Mice; Phosphodiesterase

Indexed keywords

ANTIPRURITIC AGENT; CYCLIC AMP; E 6005; PHOSPHODIESTERASE IV INHIBITOR; UNCLASSIFIED DRUG; METHYL 4-(((3-(6,7-DIMETHOXY-2-(METHYLAMINO)QUINAZOLIN-4-YL)PHENYL)AMINO)CARBONYL)BENZOATE; PHTHALIC ACID DERIVATIVE; QUINAZOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ATOPIC DERMATITIS; CONTROLLED STUDY; LETTER; MALE; MOUSE; NONHUMAN; PRURITUS; SCRATCHING; SINGLE DRUG DOSE; SKIN NERVE; TREATMENT RESPONSE; ANIMAL; DERMATITIS, ATOPIC; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; INFLAMMATION; METABOLISM; SIGNAL TRANSDUCTION; SKIN;

ANIMALS; ANTIPRURITICS; CYCLIC AMP; DERMATITIS, ATOPIC; DISEASE MODELS, ANIMAL; INFLAMMATION; MALE; MICE; PHOSPHODIESTERASE 4 INHIBITORS; PHTHALIC ACIDS; PRURITUS; QUINAZOLINES; SIGNAL TRANSDUCTION; SKIN;

EID: 84899522014     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/exd.12377     Document Type: Letter

References (28)

1. Bos J D, Brenninkmeijer E E, Schram M E et al. Exp Dermatol 2010: 19: 325-331.
2. Grimstad O, Sawanobori Y, Vestergaard C et al. Exp Dermatol 2009: 18: 35-43.
3. Wilson S R, The L, Batia L M et al. Cell 2013: 155: 285-295.
4. Tsujii K, Andoh T, Ui H et al. J Pharmacol Sci 2009: 109: 388-395.
5. Andoh T, Haza S, Saito A et al. Exp Dermatol 2011: 20: 894-898.
6. Andoh T, Saito A, Kuraishi Y. J Invest Dermatol 2009: 129: 2854-2860.
7. Doherty A M. Curr Opin Chem Biol 1999: 3: 466-473.
8. Hoppmann J, Bäumer W, Galetzka C et al. J Pharm Pharmacol 2005: 57: 1609-1617.
9. Bäumer W, Hoppmann J, Rundfeldt C et al. Inflamm Allergy Drug Targets 2007: 6: 17-26.
10. Harada D, Takada C, Nosaka Y et al. Int Immunopharmacol 2009: 9: 55-62.
11. Akama T, Baker S J, Zhang Y K et al. Bioorg Med Chem Lett 2009: 19: 2129-2132.
12. Hanifin J M, Chan S C, Cheng J B et al. J Invest Dermatol 1996: 107: 51-56.
13. Ishii N, Shirato M, Wakita H et al. J Pharmacol Exp Ther 2013: 346: 105-112.
14. Yamaguchi T, Maekawa T, Nishikawa Y et al. J Dermatol Sci 2001: 25: 20-28.
15. Maekawa T, Yamaguchi-Miyamoto T, Nojima H et al. Jpn J Pharmacol 2002: 90: 193-196.
16. Chujor C S, Hammerschmid F, Lam C. J Invest Dermatol 1998: 110: 287-291.
17. Luo M, Jones S M, Phare S M et al. J Biol Chem 2004: 279: 41512-41520.
18. Andoh T, Kuraishi Y. Eur J Pharmacol 1998: 353: 93-96.
19. Andoh T, Kuraishi Y. Mol Brain Res 2005: 137: 263-266.
20. Zhu Y, Wang X R, Peng C et al. Int Immunopharmacol 2009: 9: 1332-1336.
21. Steinhoff M, Neisius U, Ikoma A et al. J Neurosci 2003: 23: 6176-6180.
22. Barreto E O, Carvalho V F, Lagente V et al. Int Immunopharmacol 2004: 4: 755-762.
23. Matsuda H, Watanabe N, Geba G P et al. Int Immunol 1997: 9: 461-466.
24. Arai I, Tsuji M, Takeda H et al. Exp Dermatol 2013: 22: 669-671.
25. Baumer W, Hoppmann J, Rundfeldt C et al. Inflamm Allergy Drug Targets 2007: 6: 17-26.
26. Takano N, Arai I, Hashimoto Y et al. Eur J Pharmacol 2004: 495: 159-165.
27. Kress M, Rodl J, Reeh P W. Neuroscience 1996: 74: 609-617.
28. Bhave G, Zhu W, Wang H et al. Neuron 2002: 35: 721-731.